What a “surprise”, Neostem is hot!

On a recent release by Aegis Capital the NY-based biotech Neostem has been upgraded to a buy rating and a $2.5 price target. The company which has been undervalued in the cell therapy industry, has four promising platforms, including its leading candidate AMR-001 for repair of heart muscle function following an acute myocardial infarction. Most of the company's upgraded rating …